Contact

info@syndevrx.com

1 Broadway # 14, Cambridge, MA 02142

Are Metabolic Hormones the Next Frontier in Cancer Treatment?

With a global epidemic of obesity and diabetes and their known relationship to cancer, researchers and oncologists are turning their attention to metabolic hormones as promising new targets for cancer treatment.

Read More

Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy

Patients that are not cured with surgery or radiation are largely treated with endocrine therapies that target androgens or the androgen receptor (AR), a major driver of PCa. In response to androgen deprivation, most PCas progress to castrate resistant PCa. Epidemiological studies suggest that high-fat diets play important roles in PCa progression. Lipid metabolism rewires […]

Read More

The Link Between Cancer and Metabolic Dysfunction

Technology Networks recently spoke with Jim Shanahan, co-founder, chief business officer and director of SynDevRx, to explore the impact of metabolic dysfunction on treatment outcomes and learn more about the company’s lead compound SDX-7320.

Read More

High-fat diet impairs immune activity, boosts tumor growth

Obesity has been linked to increased risk for over a dozen different types of cancer, as well as worse prognosis and survival. Over the years, scientists have identified obesity-related processes that drive tumor growth, such as metabolic changes and chronic inflammation, but a detailed understanding of the interplay between obesity and cancer has remained elusive. […]

Read More

Cancer cells harness insulin for performance enhancement

Endogenous hyperinsulinemia has been proposed as one of the causal factors contributing to the association between obesity, diabetes, and increased cancer risk and mortality. Previous studies have examined the mechanisms through which hyperinsulinemia promotes cancer progression, but it is not understood how hyperinsulinemia contributes to cancer incidence. Disruption of cell polarity is an early event […]

Read More

SynDevRx Announces Positive Data from Phase 1 Safety Trial of SDX-7320 in Late Stage Cancer Patients

SynDevRx, Inc., a clinical-stage oncology company, has submitted results of its Phase 1 dose escalation safety study in late-stage cancer patients with progressive, metastatic solid tumors to the United States Food and Drug Administration (FDA). The study’s primary endpoint was to establish the maximum tolerated dose and dosing schedule and the recommended Phase 2 dose […]

Read More

Metabolic Health, Insulin and Breast Cancer – Why Oncologists Should Care About Insulin

While diabetes/insulin-resistance and breast cancer are distinct diseases, insulin-signaling plays a central role in both illnesses. Insulin activates key cancer processes including EMT, tissue inflammation, motility, and angiogenesis. There are key opportunities to impact and prevent hyperinsulinemia during breast cancer prevention, surgical assessment, and chemotherapy. While it is not standard of care to test for […]

Read More

Decellularized extracellular matrix scaffolds identify full-length collagen VI as a driver of breast cancer cell invasion in obesity and metastasis

We show that decellularized ECM from tumor-bearing and obese mammary glands drives TNBC cell invasion. Proteomics of the ECM from the obese mammary gland led us to identify full-length collagen VI as a novel driver of TNBC cell invasion whose abundance in tumor stroma increases with body mass index in human TNBC patients. Last, we […]

Read More

SynDevRx Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by PI3K/Akt/mTOR Cancer Therapies and Restores Insulin Sensitivity, Preclinical Studies Show

SynDevRx, Inc., a clinical-stage oncology company, announces the completion of a series of preclinical studies demonstrating that its anti-cancer drug candidate, SDX-7320, inhibits PI3K/Akt inhibitor-induced hyperglycemia and subsequent hyperinsulinemia in normal mice and inhibits tumor growth in multiple models of HR+ breast cancer. The company’s ongoing research places them at the vanguard of metabo-oncology, an emerging field of cancer research that focuses on the role metabolic hormones play in the development and progression of many common cancers, as well as tumor resistance developed in response to certain treatment.

Read More

Metabolic Hormone Leptin Linked to COVID-19

The hormone leptin that connects the body’s metabolism and immune response system may explain why COVID-19 is so dangerous for people with obesity. “The problem for people with obesity is that their leptin levels are always high, and that can affect the response to a COVID-19 infection,” said Candida Rebello, PhD, RD, lead author of […]

Read More